多药耐药相关蛋白及肺耐药蛋白在人直肠癌组织中的表达及临床意义

目的　检测多药耐药相关蛋白（ＭＲＰ） 及肺耐药蛋白（ＬＲＰ） 在人直肠癌组织中的表达，探讨其与临床分期、分化程度及预后的关系。方法　采用免疫组织化学技术法检测５７ 例人直肠癌组织中ＭＲＰ及ＬＲＰ的表达。结果　５７ 例人直肠癌组织中可检测到ＭＲＰ表达者２８ 例，占４９．１ ％ ；ＬＲＰ表达者２４ 例，占４２．１ ％ ；二者同时表达者１０ 例，占１７ ．５％ ；有ＭＲＰ或ＬＲＰ表达者４２ 例，占７３ ．７ ％ ；两蛋白表达阳性率与肿瘤分期、分化程度无显著相关（ Ｐ＞ ０ ．０５） 。ＭＲＰ表达阳性者术后生存期明显低于该蛋白阴性者（ Ｐ＜ ０．０５） ，而ＬＲＰ的表达则与预后无显著相关；两蛋白表达无明显相关性（ Ｐ＞ ０．０５） 。结论　ＭＲＰ可能是判断人直肠癌预后的指标之一，对直肠癌患者综合治疗的实施具有指导意义。

Expression of multidrug resistance associated protein (MRP) and lung resistance protein (LRP) in human rectal carcinomas and its clinical significance

Objective To investigate the expression and clinical significance of multidrug resistance associated protein(MRP) and lung resistance protein(LRP) in rectal carcinoma. Methods Fiftyseven paraffin embeded primary rectal carcinoma specimens were examined by immunohistochemical staining. Results Of the 57 tumour specimens examined, 28(49.1%) and 24(42.1%) were positively immunostaned for MRP and LRP, respectively. Co expression of the two proteins was observed in 10(17.5%) specimens. Positive immunostaning of either of the two proteins was not correlated with cell differentiation and Dukes stage ( P >0.05). Patients with MRP positive tumours had shorter survival than MRP negative patients ( P <0.05). No such correlation was found for LRP expression, nor was found between MRP and LRP expression. Conclusion Positive MRP expression in rectal carcinoma appears to be an independant factor of prognostic significance. To examine its expression may help guide rational comprehensive therapy of rectal carcinoma.